Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection

AAPS PharmSci

Volumn 2, Issue 1, 2000, Pages 1-8

  Sabo, John P ^a   Lamson, Michael J ^a   Leitz, Gerhard ^a   Yong, Chan Loi ^a   MacGregor, Thomas R ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Cotrimoxazole; Drug Interaction; Enzyme Induction; Lamivudine; Nevirapine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METABOLISM; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; NEVIRAPINE; NUCLEOSIDES; PLACEBOS; REVERSE TRANSCRIPTASE INHIBITORS; SEX FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 18044403430     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps020101     Document Type: Article

References (19)

1. Piscitelli SC, Flexner C, Minor JR, Polis MA. Drug interactions in patients with human immunodeficiency virus. Clin Inf Dis. 1996;23:685-693.
2. Barry M, Mulchahy F, Merry, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokin. 1999;36:289-304.
3. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetics interactions. Clin Pharmacokin. 1997;32:210-258.
4. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin hvest Drugs. 1996;5:1183-1199.
5. Lamson MJ, Cort S, Sabo JP, Keirns JJ. Assessment of nevirapine oral bioavailability in healthy volunteers following oral and intravenous administration. Pharm Res. 1995;12:5-415.
6. Riska PR, Lamson MJ, MacGregor TR, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Disp. 1999;27:895-901.
7. Havlir D, Cheeseman SH, McLaughlin MM, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Inf Dis. 1995;171:537-545.
8. Lamson MJ, Cort S, Sabo JP, MacGregor TR, Keirns JJ. Effects of gender on the single and multiple dose pharmacokinetics of nevirapine. Pharm Res. 1995;12:5-101.
9. Murphy R, Sommadossi JP, Lamson MJ, Hall DB, Myers MM, Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in HIV-1 infected individuals. J Inf Dis. 1999;179:1116-1123.
10. Van Leeuwen R, Lange JMA, Hussey EK, Donn KH, Hall ST, Harker AJ. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992;6:1471-1475.
11. Moore KHP, Yuen GJ, Raasch RH, Eron JJ, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharm Ther. 1996;59:550-558.
12. Johnson MA, Moore KHP, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokin. 1999;36:41-66.
13. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med. 1995;333:1662-1669.
14. Pav JW, Rowland LS, Korpalski DJ. HPLC-UV method for quantitation of nevirapine in biological matrices following solid-phase extraction. J Pharm Biomed Anal. 1999;20:91-98.
15. Beal SL, Sheiner LB. NONMEM Users Guide, Parts I-VI, Division of Clinical Pharmacology, NONMEM Project Group, University of California at San Francisco, San Francisco, CA, 1979-1992.
16. Jonsson EN, Karlsson MO. Xpose - An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51.
17. S-PLUS Version 4.5. Data Analysis Products Division, MathSoft, Seattle, WA.
18. Sweeney KR, Hsyu P-H, Statkevick P. Renal disposition and drug interaction screening of (-)-2′-deoxy-3′-thiacytidine (3TC) in the isolated perfused rat kidney. Pharm Res. 1995;12:1958-1963.
19. Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Disposition. 1999;20:285-291.